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 The renin – angiotensin system (RAS) 
serves a critical homeostatic function in 
the regulation of body L uid volumes and 
blood pressure (BP). But in patients with 
chronic kidney disease (CKD), an inad-
equately suppressed RAS with associated 
volume expansion may be largely respon-
sible for the very high prevalence of 
hypertension and the associated down-
stream consequences. Nonetheless, in the 
context of renal disease progression, it is 
the BP-independent deleterious e1 ects of 
angiotensin II mediated through angi-
otensin II type 1 (AT 1 ) receptors that have 
received the greatest emphasis. Accord-
ingly, current CKD management guide-
lines emphasize angiotensin-converting 
enzyme inhibitors or AT 1 receptor block-
ers as speci c antiproteinuric and reno-
protective therapy independent of their 
antihypertensive effects. Indeed, RAS 
blockade at more than one step of the cas-
cade is being recommended by some in 
the continuing search for ever more 
 complete RAS inhibition. ? e results of 
Benndorf  et al. 1 (this issue) in AT 2 
 receptor–de cient mice add to a small 
and growing but still-controversial litera-
ture that suggests that the biology of 
downstream angiotensin II signaling in 
CKD may be more complex and not 
always predictive of deleterious conse-
quences. Given that the AT 2 receptor is 
generally postulated to antagonize the 
e1 ects of AT 1 receptor activation, 2 the 
data of Benndorf  et al. 1 imply that the 
greater severity of renal damage observed 
in  AT  2   – / –  mice  a$ er 5 / 6 ablation may be a 
consequence of either some unantago-
nized AT 1 e1 ect or, alternatively, the loss 
of an independently beneficial AT 2 
e1 ect. 
 A plethora of potential AT 1 receptor–
mediated deleterious mechanisms have 
been postulated through investigations in 
a variety of disease models and  in vitro 
systems. 1,2 ? ese range from increased 
oxidative stress to an activation of growth 
factors, cytokines, chemokines, and pre-
inL ammatory and  brogenic mediators 
through G protein–coupled and G pro-
tein–independent signaling cascades 
involving mitogen-activated protein 
kinases, extracellular signal–regulated 
kinases, and JAK / STAT pathways. How-
ever, pressure (barotrauma) and tissue 
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 Angiotensin  II is believed to mediate blood pressure-independent 
progressive renal damage in chronic kidney disease (CKD). The evidence 
is less definitive than has been implied, and the studies by Benndorf  et al. 
suggest that angiotensin II, acting through its type 2 receptor, may even 
have beneficial effects, although the responsible mechanisms remain to 
be defined. These and other data suggest that the concept of blood 
pressure-independent angiotensin signaling being uniformly 
deleterious in CKD is an oversimplification that needs re-evaluation.  
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stress and / or injury  per se can also acti-
vate many of these downstream path-
ways. 3 ? erefore, controversy persists as 
to the precise contribution of BP-depend-
ent and -independent pathways to the 
observed tissue damage in the  in vivo 
models, given that the BP-independence 
has only been established in such studies 
by isolated tail-cuff BP measurements 
that are clearly inadequate for this objec-
tive. 4 But the fact that these pathways can 
also be initiated by angiotensin II in  in 
vitro systems has been cited to support 
the likely BP-independence of the  in vivo 
e1 ects. However, such inferences may not 
be valid. Clearly, these deleterious path-
ways are not activated by a low-salt diet 
despite large increases in angiotensin II 
levels. ? e elegant studies of renal cross-
transplantation between  AT  1    −  /  −   and 
wild-type control mice reported by Crow-
ley  et al. also provide a striking and fairly 
de nitive illustration of the inability of 
angiotensin II  per se to trigger adverse 
signaling pathways in cardiac tissue. 5 
While kidney AT 1 receptors were found 
to be required for the hypertensive 
response to angiotensin II infusion, in the 
absence of hypertension (in wild-type 
mice with kidneys transplanted from 
 AT  1    −  /  −   animals), no cardiac hypertrophy 
or injury was observed despite the pres-
ence of AT 1 receptors and high concen-
trations of infused angiotensin II. 
Conversely,  AT  1    −  /  −   mice with kidneys 
transplanted from  AT  1    +  /  +   mice devel-
oped hypertension and cardiac hypertro-
phy and damage comparable to that seen 
in wild-type mice when exogenous angi-
otensin was infused , even though cardiac 
AT 1 receptors were lacking. ? us, hyper-
tension is both necessary and su.  cient, 
whereas cardiac AT 1 receptors are neither 
necessary nor su.  cient, for cardiac injury 
a$ er exogenous angiotensin II infusion. 
Collectively, such data indicate a context-
appropriate regulation of AT 1 receptor–
mediated signaling pathways. Moreover, 
these results, although contrary to con-
ventional wisdom, are nevertheless 
entirely consistent with the recent clinical 
cardiovascular trials that have failed to 
demonstrate the expected BP-independ-
ent superiority of RAS blockade over 
other antihypertensive classes for cardio-
vascular end points. 6 
see original article on page 1039
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a$ er 5 / 6 ablation ( Figure 1 ). Evidence of 
AT 1 receptor upregulation or a greater 
severity of hypertension with the use of 
BP radiotelemetry, as might have been 
anticipated, was not found. However, 
despite similar systemic BPs, P GC pro les 
may have di1 ered because of di1 erences 
in e1 erent resistance. Given the postulated 
role of the AT 2 receptor in nitric oxide 
production that may normally exert a 
tonic vasodilatory e1 ect on the e1 erent 
arteriole, 2 it is possible that in states of 
marked P GC elevation (as in a$ er 5 / 6 abla-
tion), a loss of such AT 2 receptor–medi-
ated efferent vasodilation becomes 
pathogenetically more important. 
Although endothelial nitric oxide syn-
thase expression was not di1 erent, a loss 
of neuronal nitric oxide synthase (not 
examined) may potentially be more 
important in CKD models. 9 Such a loss, 
possibly acting through both BP-depend-
ent and BP-independent mechanisms, has 
been postulated to promote progressive 
glomerular injury in a variety of models, 
including the 5 / 6 ablation model.
The increased levels of asymmetric 
 Nevertheless, the potential for BP-inde-
pendent deleterious e1 ects of angiotensin 
II might be greater in the kidney because 
of its capacity for preferential efferent 
arteriolar constriction. Indeed, this mech-
anism is postulated to play a major role in 
the glomerular hypertension observed in 
the 5 / 6 renal ablation model. ? e meth-
odologic limitations of such micropunc-
ture data obtained under anesthesia have 
been reviewed in detail elsewhere. 7 More-
over, preferential angiotensin II–mediated 
vasoconstriction has classically been dem-
onstrated in low-perfusion pressure states 
associated with reduced macula densa 
L ow (renal artery stenosis, hypovolemia), 
which stimulate not only renin release but 
also concurrent cyclooxygenase-2-medi-
ated prostaglandin E 2 release from the 
macula densa. Prostaglandin E 2 attenuates 
a1 erent but not e1 erent responses to angi-
otensin II. ? is results in selective e1 erent 
constriction and a context-appropriate 
preferential preservation of glomerular 
 ltration rate and glomerular capillary 
pressure P GC in renal hypoperfusion 
states 8 — hence the sensitivity to nonster-
oidal anti-inL ammatory drug (NSAID)–
induced acute renal failure in such states . 
It is unlikely that a selective angiotensin 
II–mediated e1 erent constriction is a fea-
ture of ambient glomerular hemodynam-
ics in the volume-replete normotensive 
state or the volume-expanded hyperten-
sive CKD models. Moreover, substantial 
evidence indicates that pathogenic 
glomerular hypertension in CKD models 
is primarily a consequence of an impair-
ment of the autoregulatory responses of 
the dilated a1 erent arterioles that nor-
mally protect the glomerular capillaries 
from transmission of systemic BP eleva-
tions, episodic or sustained. 3 ? is results 
in a greatly reduced BP threshold for 
glomerular injury, as current guidelines 
now recognize. 6 Consistent  with such 
interpretations, the marked di1 erences 
seen in the susceptibility to glomerulo-
sclerosis across species and rodent strains 
a$ er 5 / 6 ablation largely parallel the dif-
ferences in their susceptibilities to develop 
hypertension. 3 
 Similarly, no evidence of the BP-inde-
pendent glomeruloprotection by RAS 
blockade in the 5 / 6 ablation model is seen 
when BP is measured radiotelemetrically, 
as would be expected with angiotensin 
II–mediated efferent constriction. 3 
Glomeruloprotection is found to be pro-
portional to the achieved BP reductions 
with most   antihypertensive agents, 
including angiotensin-converting enzyme 
inhibitors and angiotensin receptor block-
ers, but not calcium channel blockers. 
Unlike other antihypertensives, calcium 
channel blockers predictably further 
impair renal autoregulation, lower the BP 
threshold for glomerulosclerosis, and 
steepen the slope of the relationship 
between BP and glomerulosclerosis. 3 
Accordingly, less glomeruloprotection is 
achieved for a given BP reduction. ? ese 
e1 ects are relevant to the interpretations 
of the clinical trial data showing superior 
renal outcomes with RAS blockade. Such 
trials have either used calcium channel 
blockers in the comparator arms or failed 
to achieve equal BP  lowering. 3 
 Given this background, how might the 
AT 2 receptor de ciency result in increased 
renal damage in the 5 / 6 ablation model? 
On balance, the data suggest a loss of a 

















 Figure 1  |  Blood pressure and angiotensin-mediated pathways of CKD progression. The 
deleterious pathways are indicated by solid lines, whereas pathways with potential beneficial effects 
are indicated by broken lines. A question mark indicates that the evidence is still controversial. 
The cellular and molecular mechanisms responsible for the compensatory adaptations, including 
renal vasodilation and glomerular hypertrophy and their regulation, have not yet been defined. 
Similarly, the mechanisms responsible for the afferent arteriole autoregulatory impairment after 
approximately three-quarters of   functional renal mass loss remain to be established. 
GC, glomerular capillary; NO, nitric oxide; R A , afferent resistance ; R E, efferent resistance . 
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dimethylarginine that were noted, perhaps 
in part as a result of greater renal function 
loss in the AT 2 receptor-de cient mice, 
may have further depressed nitric oxide 
synthesis and contributed to glomerular 
hypertension and renal damage. Clearly, 
much  more work, including con rmation 
of these e1 ects of AT 2 receptor-de ciency 
on other genetic backgrounds, needs to be 
done before the responsible mechanisms 
are elucidated and the overall signi cance 
of these observations in AT 2 receptor–
de cient mice is established. 
 Nevertheless, such observations, com-
bined with the data of Crowley  et al. 5 and 
the lack of adverse downstream signaling 
a$ er a low-salt diet, suggest that current 
formulations regarding the uniformly del-
eterious consequences of angiotensin sig-
naling in CKD may be overly simplistic 
and need re-examination. For instance, 
even AT 1 receptor–mediated BP-inde-
pendent signaling has the potential for 
beneficial effects, as suggested by the 
intriguing observations of Nishida  et al. 
that AT 1 receptor de ciency in bone mar-
row–derived macrophages may promote 
increased renal fibrosis. 10 Similarly, 
although severe AT 1 receptor–mediated 
afferent constriction, like high-dose 
 angiotensin II infusion, causes ischemia, 
more modest constriction at physiologic 
angiotensin II concentrations would in 
fact be expected to be protective by reduc-
ing glomerular BP transmission. Addi-
tionally, angiotensin II, even at subpressor 
levels, has also been noted to potentiate 
the myogenic responses to pressure 
changes, which would also be expected to 
be protective. 11 ? e fact that more com-
plete dual RAS blockade with ramipril and 
telmisartan in the ONTARGET trial not 
only failed to provide additional  bene ts 
as compared with monotherapy but in fact 
had adverse renal e1 ects, 12  only reinforces 
the need for such a  reassessment . 
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